Chargement en cours...

BRAF(V600) mutant non-small-cell lung cancer resistant to Vemurafenib

Vemurafenib has shown significant activity in V600 mutant melanoma; however the role of this agent in Lung adenocarcinoma with an activating BRAF mutation is still evolving. One of our patients had a rare activating BRAF mutation detected through tumor exome sequencing, which led to a switch from he...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Int J Clin Exp Pathol
Auteurs principaux: Karak, Fadi El, Assi, Tarek, Kourie, Hampig Raphael, Rassy, Elie El, Chebib, Ralph, Ghor, Maya, Tabchi, Samer
Format: Artigo
Langue:Inglês
Publié: e-Century Publishing Corporation 2015
Sujets:
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4440164/
https://ncbi.nlm.nih.gov/pubmed/26045855
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!